Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next
Moderna shares fell about 1% to $39.20 premarket Wednesday after a 17% surge the day before. The company raised its 2025 revenue estimate to $1.9 billion and cut its operating-expense outlook by $200 million. Moderna expects several vaccine approvals and trial updates in 2026, with Q4 results due February 13. U.S. retail vaccination rates dropped 26% in 2025, less than expected.